Predictable repeatability issues with GeneXpert-Xpert MTB/RIF (version 4) derived rifampicin resistant tuberculosis results from South India: Appreciating the limits of a technological marvel!

8Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Background: GeneXpert MTB/RIF (Xpert), the fully automated cartridge-based nucleic acid amplification test for simultaneous identification of Mycobacterium tuberculosis complex and rifampicin resistance (RR), directly from samples is considered as a game changer for tuberculosis (TB) control programs worldwide. Methods: We are reporting serious issues with repeatability among a subgroup of Xpert (Version 4) identified RR results from South Indian state recently switched to Xpert by the National TB control program. Results: We have demonstrated that poor repeatability is frequently associated with those Xpert derived RR results, identified by detection of delayed amplification of any probe in the presence of positive analyte results for all probes. Another significant contributing factor was found to be lower bacterial loads in samples. The repeat tests were done by Xpert and/or by line probe assay depending on smear positivity. The finding is worrying as Xpert is recommended over other tests due to its reportedly better performance among low bacterial load samples such as pediatric, extra-pulmonary, HIV-TB co-infected, and smear negative pulmonary TB and the same samples, it seems are more likely to cause error prone RR results. Conclusions: We recommend for additional genotypic tests with specific mutant probes for detecting mutations at rpoB hot sites and growth based tests for all Xpert derived RR-TB cases identified by the above algorithm for confirmation of the presence of mutation, based on our available data.

References Powered by Scopus

Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults

601Citations
N/AReaders
Get full text

Advances in tuberculosis diagnostics: The Xpert MTB/RIF assay and future prospects for a point-of-care test

382Citations
N/AReaders
Get full text

Evaluation of the analytical performance of the Xpert MTB/RIF assay

375Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Evaluation of GeneXpert Mycobacterium tuberculosis/Rifampin for the detection of Mycobacterium tuberculosis complex and rifampicin resistance in nonrespiratory clinical specimens

30Citations
N/AReaders
Get full text

Interpretation of discordant rifampicin susceptibility test results obtained using GeneXpert vs phenotypic drug susceptibility testing

29Citations
N/AReaders
Get full text

Validation of the GenoType<sup>®</sup> MTBDRplus Ver 2.0 assay for detection of rifampicin and isoniazid resistance in Mycobacterium tuberculosis complex isolates at UZCHS-CTRC TB research laboratory

10Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Sanker, P., Kottuthodi, R., Ambika, A., Santhosh, V., Balakrishnan, R., Mrithunjayan, S., & Moosan, H. (2017). Predictable repeatability issues with GeneXpert-Xpert MTB/RIF (version 4) derived rifampicin resistant tuberculosis results from South India: Appreciating the limits of a technological marvel! Biomedical and Biotechnology Research Journal, 1(1), 76–80. https://doi.org/10.4103/bbrj.bbrj_6_17

Readers over time

‘18‘20‘21‘22‘23‘2402468

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 6

75%

Lecturer / Post doc 1

13%

Researcher 1

13%

Readers' Discipline

Tooltip

Medicine and Dentistry 7

88%

Nursing and Health Professions 1

13%

Save time finding and organizing research with Mendeley

Sign up for free
0